GW is a major pharmaceutical company and shouldn't be grouped together with "sketchy" weed companies, CNBC's Jim Cramer said Wednesday on "Mad Money."
CEO Justin Gover told Cramer during an interview on "Mad Money" he agrees with Cramer's assessment of GW Pharmaceuticals — and all he can do is continue focusing on the company's core medicine and pipeline.
GW's focus is now showing results, as the company exceeded $100 million in revenue during the first six months of 2019, the CEO said.
Gover said he is "very satisfied" with the level of awareness of Epidiolex. The company can further benefit through increased education on what the medicine does, how it's dosed and who benefits, he said.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
Why It's Important
GW is far from the only sole medical cannabis company in the space; the company is "20 years in the making," Gover said.
The company has benefited from "real, rigorous science" around safety in CBD, efficacy in patients and proper dosing.
"What we are offering to patients and physicians is quite distinct from other cannabis-based products,."
"This is a rigorously tested, appropriately manufactured, FDA-approved pharmaceutical [product] that patients can obtain through insurance coverage with all the hallmarks of a modern medication they expect from any other type of medication that they would seek to take."
GW is only a few months into its Epidiolex "journey," and there is a lot of room for its medicine to grow in the marketplace over the coming years, the CEO said.
GW Pharma shares were trading higher by 3.38% at $172 at the time of publication Thursday.
GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake
GW Pharma Rallies On Strong Q2 Epidiolex Sales, Says European Approval Expected In October
Photo courtesy of GW Pharma.
See more from Benzinga
- IAC CEO Says Match Group Can 'Stand On Its Own'
- Analysts Upgrade Roku, Stock Soars After Big Q2 Earnings Beat
- Kraft Issues Preliminary Report With .2B In Charges, Announces Delayed 10-Q Filing
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.